Gion N, Stavrou P, Foster C S
Ocular Immunology and Uveitis Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts 02114, USA.
Am J Ophthalmol. 2000 Jun;129(6):764-8. doi: 10.1016/s0002-9394(00)00482-7.
To describe the clinical course and treatment with immunomodulatory agents in patients with tubulointerstitial nephritis and uveitis syndrome.
Retrospective analysis of the charts of six patients with tubulointerstitial nephritis and uveitis syndrome.
The mean (+/-SD) age was 24.3 (+/-16.5) years, range 13 to 49 years. Four patients were children, and two were adults. Three were men, and three were women. Five of the six patients had anterior uveitis, and one had panuveitis. All patients had several relapses despite treatment with topical, regional, and oral steroids and methotrexate in one case. The introduction or modification of immunosuppressants (methotrexate, azathioprine, or cyclosporin A) achieved control of the uveitis and prevented relapses over a mean (+/-SD) follow-up period of 19.66 (+/-10.01) months, range 6 to 34 months. No treatment-related side effects were observed.
Tubulointerstitial nephritis and uveitis syndrome is a distinct disease entity in which the nephritis typically resolves, but the uveitis often becomes chronic and is treatment resistant. Immunomodulatory agents can achieve control of the inflammation and prevent relapses.
描述肾小管间质性肾炎和葡萄膜炎综合征患者的临床病程及免疫调节药物治疗情况。
对6例肾小管间质性肾炎和葡萄膜炎综合征患者的病历进行回顾性分析。
平均（±标准差）年龄为24.3（±16.5）岁，范围为13至49岁。4例为儿童，2例为成人。3例为男性，3例为女性。6例患者中有5例患有前葡萄膜炎，1例患有全葡萄膜炎。尽管1例患者接受了局部、区域和口服类固醇以及甲氨蝶呤治疗，但所有患者均有多次复发。在平均（±标准差）19.66（±10.01）个月（范围6至34个月）的随访期内，引入或调整免疫抑制剂（甲氨蝶呤、硫唑嘌呤或环孢素A）实现了对葡萄膜炎的控制并预防了复发。未观察到与治疗相关的副作用。
肾小管间质性肾炎和葡萄膜炎综合征是一种独特的疾病实体，其中肾炎通常会缓解，但葡萄膜炎往往会发展为慢性且对治疗耐药。免疫调节药物可实现对炎症的控制并预防复发。
Zotero 插件